Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2025 CLL Highlights
10 February 2026 | Virtual Webinar
Post-ASH 2025 CLL Highlights
Featuring presentations & discussions on selected CLL abstracts from the 67th ASH Annual Meeting and Exposition
Tuesday 10 February | 08:00 – 10:00 CST/ 14:00 – 16:00 GMT/ 15:00 – 17:00 CET
Chair: Kerry Rogers | Moderators: Deborah Stephens & Moritz Fürstenau
The Post-ASH 2025 CLL Highlights has been supported by AstraZeneca (Diamond Sponsor), Genentech (Gold Sponsor), Lilly (Gold Sponsor) and Ascentage (Silver Sponsor). Supporters have no influence over the production of content.
Explore the presentations and panel discussions below
Session 1: Novel treatment approaches in CLL
Fixed-duration versus continuous targeted treatment for previously untreated CLL: results from the randomized CLL17 trial
Othman Al-Sawaf University Hospital of Cologne, Cologne, Germany
MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: NCRI FLAIR trial
Surita Dalal University of Leeds & Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: results from the GAIA/CLL13 trial
Carsten Niemann Copenhagen University Hospital, Copenhagen, Denmark
Panel Discussion
Session 2: Novel BTKi monotherapy approaches for CLL
Updates of R/R CLL with prior exposure to BTK inhibitors and/or BCL-2 inhibitors in the Phase I trial of rocbrutinib, a novel covalent and non-covalent BTK inhibitor
Jennifer Woyach The Ohio State University Comprehensive Cancer Center, Afghanistan
Pirtobrutinib vs ibrutinib in treatment-naïve and R/R CLL/SLL: results from the Phase III study comparing a non-covalent and covalent BTK inhibitor
Jennifer Woyach The Ohio State University Comprehensive Cancer Center, Afghanistan
Pirtobrutinib outcomes in second-line CLL/SLL after first-line cBTKi therapy: a pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies
Toby Eyre Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: first results from a randomized Phase III study examining a non-covalent BTK inhibitor in untreated patients
Wojciech Jurczak Jagiellonian University, Krakow, Poland
Panel Discussion
Session 3: Novel BTKi combination approaches for CLL
A post-hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: AMPLIFY trial
Jennifer Brown Dana-Farber Cancer Institute, Boston, MA, United States
Nemtabrutinib plus venetoclax in R/R CLL/SLL: results from the dose escalation and confirmation segment of the Bellwave-010 study
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
A Phase II study with tafasitamab and zanubrutinib in newly diagnosed CLL/SLL
Georgios Pongas University of Miami Miller School of Medicine, Miami, FL, United States
Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive CLL/SLL: initial results from an ongoing Phase I/Ib study
Jacob Soumerai Massachusetts General Hospital, Boston, MA, United States
Panel Discussion
Session 4: BTK degraders for CLL
Bexobrutideg, a novel BTK degrader, demonstrates rapid and durable clinical responses in R/R CLL
Zulfa Omer University of Cincinnati, Cincinnati, OH, United States
Updated efficacy and safety results of the BTK degrader BGB-16673 in patients with R/R CLL/SLL from the CaDAnCe-101 study
Meghan Thompson Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Panel Discussion
Session 5: Advances with targeted therapies and immunotherapies for CLL
Epcoritamab combinations demonstrate promising efficacy in patients with Richter's transformation: first results from arms 2B and 2C of the EPCORE CLL-1 trial
Tamar Tadmor Bnai Zion Medical Center, Haifa, Israel
Superior real-world outcomes of lisocabtagene maraleucel in CLL
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Results of a registrational Phase II study of lisaftoclax monotherapy for patients with R/R CLL/SLL who had failed BTKis
Keshu Zhou Zhengzhou University, Zhengzhou, China
Panel Discussion
